01.03.2017 Evonik Industries AG  DE000EVNK013

DGAP-News: Evonik Industries AG: Changes in the Executive Board

DGAP-News: Evonik Industries AG / Key word(s): Change of Personnel Evonik Industries AG: Changes in the Executive Board 01.03.2017 / 12:30 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Changes in the Executive Board - Christian Kullmann to succeed Klaus Engel in May - Harald Schwager to become deputy chief executive officer - COO function to be dropped Essen. Klaus Engel (60), Chairman of Evonik's Executive Board, is to hand over to his designated successor Christian Kullmann (47). Engel will be leaving the company at the end of the Annual Shareholders' Meeting on May 23, 2017. Mr. Kullmann will then take over as chairman. The Supervisory Board announced these resolutions after its meeting today. "We thank Mr. Engel for his service to the company and for his outstanding achievements," said Werner Müller, Chairman of the Supervisory Board. "Mr. Engel has transformed Evonik from a conglomerate to a company focused on chemicals, successfully listed it on the stock market, and developed it into a leading specialty chemicals company with outstanding prospects." Müller specifically mentioned the acquisition of the Air Products specialty additives business, which Engel achieved in May 2016. Engel was originally appointed to the Board of Management of what was then Degussa in 2007, becoming Chairman in 2009. He has worked closely with Christian Kullmann for many years. "Having spent more than three decades in fascinating managerial roles in the chemical industry, Evonik's tenth anniversary seems to me to be an appropriate time to ensure a smooth transition and hand over a well-tilled field to my successor," said Engel. "The goal of transforming Evonik into a listed, world-leading specialty chemicals group has been achieved. I am grateful that I was able to play a key part in shaping the development of this company over the past ten years." Christian Kullmann has worked for the company for 14 years and was appointed Deputy Chairman of the Executive Board in May 2016. His responsibilities include strategy, M&A, Legal, Communications and Investor Relations. "I sincerely thank Mr. Engel for our trustful collaboration," said Kullmann. "I look forward to taking on this new role and thank the Supervisory Board for its confidence in me." Harald Schwager (56) will be joining Evonik on September 1 as the new Deputy Chairman of the Executive Board, with responsibility for chemicals and innovation. Schwager is a chemist and a member of the Board of Executive Directors of BASF, which he will be leaving in May. "Mr. Schwager and I share the same views on how to lead and drive forward an international specialty chemicals group," said Kullmann. "I and my colleagues on the Executive Board are looking forward to working with him." Ralph Sven Kaufmann (51), Chief Operating Officer of Evonik, will be leaving the company by mutual and amicable agreement on June 30, 2017, before the scheduled end of his term of office. "Mr. Kaufmann successfully supported the transition of the newly established segments to independent operating units," said Werner Müller. "In addition, he played a key role in the restructuring of the Performance Materials segment and the integration of the new Air Products business. We thank him for his successful work." The position of Chief Operating Office on the Executive Board will not be filled. Company information Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik's corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms Disclaimer In so far as forecasts or expectations are expressed in this Investor Relations News or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release. Contact: Tim Lange Head of Investor Relations +49 201 177-3150 [email protected] Evonik Industries AG Rellinghauser Straße 1-11 45128 Essen Germany Phone +49 201 177-01 Fax +49 201 177-3475 www.evonik.com Supervisory Board Dr. Werner Müller, Chairman Executive Board Dr. Klaus Engel, Chairman Christian Kullmann, Deputy Chairman Dr. Ralph Sven Kaufmann Thomas Wessel Ute Wolf Registered Office is Essen Register Court Essen Local Court Commercial Registry B 19474 --------------------------------------------------------------------------- 01.03.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: Evonik Industries AG Rellinghauser Straße 1-11 45128 Essen Germany Phone: +49 (0) 201 177-01 Fax: +49 (0) 201 177-3475 E-mail: [email protected] Internet: www.evonik.com ISIN: DE000EVNK013, XS0911405784 WKN: EVNK01, A1TM7T Indices: MDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Luxemburg End of News DGAP News Service --------------------------------------------------------------------------- 549105 01.03.2017

Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022
Umsatzerlöse1 12.732,00 14.419,00 15.024,00 13.108,00 12.199,00 14.955,00 18.488,00
EBITDA1,2 2.165,00 2.357,00 2.150,00 2.153,00 1.837,00 2.246,00 2.510,00
EBITDA-Marge3 17,00 16,35 14,31 16,43 15,06 15,02 13,58
EBIT1,4 1.298,00 1.229,00 1.367,00 1.080,00 819,00 1.173,00 942,00
EBIT-Marge5 10,19 8,52 9,10 8,24 6,71 7,84 5,10
Jahresüberschuss1 762,00 734,00 954,00 2.127,00 479,00 767,00 555,00
Netto-Marge6 5,98 5,09 6,35 16,23 3,93 5,13 3,00
Cashflow1,7 1.758,00 1.551,00 1.704,00 1.321,00 1.727,00 1.815,00 1.650,00
Ergebnis je Aktie8 1,81 1,54 2,00 4,52 1,00 1,60 1,16
Dividende8 1,15 1,15 1,15 1,15 1,15 1,17 1,17
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2022 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: KPMG

Evonik Industries
WKN Kurs in € Einschätzung Börsenwert in Mio. €
EVNK01 17,820 Halten 8.304,12
KGV 2024e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
15,50 17,54 0,90 9,93
0,80 5,03 0,45 4,61
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
1,17 0,77 4,32 31.05.2023
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
09.05.2023 04.08.2023 07.11.2023 02.03.2023
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-0,83% -5,44% -0,64% 1,83%
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Evonik Industries AG  ISIN: DE000EVNK013 können Sie bei EQS abrufen

Chemie , EVNK01 , EVK , XETR:EVK